NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform
NeoGenomics and Ultima Genomics have announced a strategic collaboration to enhance cancer diagnostic capabilities using the UG 100 sequencing platform. NeoGenomics has purchased and will install the UG 100 sequencer at their Cambridge, UK innovation center.
The collaboration leverages Ultima's ppmSeq™ technology, which offers cost-effective and low-error sequencing. Recent improvements through the Solaris portfolio have achieved 5x yield improvements, enabling 30X coverage from just 2 nanograms of DNA - a significant advancement for liquid biopsy applications.
This partnership aims to advance oncology diagnostic solutions, particularly in areas like minimal residual disease (MRD) detection and whole genome sequencing. The UG 100 platform's unique architecture specifically addresses the needs of large-scale, cost-effective applications while maintaining high accuracy for early cancer detection.
NeoGenomics e Ultima Genomics hanno annunciato una collaborazione strategica per migliorare le capacità diagnostiche nel campo del cancro utilizzando la piattaforma di sequenziamento UG 100. NeoGenomics ha acquistato e installerà il sequenziatore UG 100 presso il proprio centro di innovazione di Cambridge, Regno Unito.
La collaborazione sfrutta la tecnologia ppmSeq™ di Ultima, che garantisce un sequenziamento economico e a basso tasso di errore. I recenti miglioramenti apportati tramite il portafoglio Solaris hanno permesso un aumento della resa di 5 volte, consentendo una copertura di 30X con soli 2 nanogrammi di DNA - un progresso significativo per le applicazioni di biopsia liquida.
Questa partnership mira a far progredire le soluzioni diagnostiche oncologiche, in particolare in ambiti come il rilevamento della malattia residua minima (MRD) e il sequenziamento dell'intero genoma. L'architettura unica della piattaforma UG 100 risponde specificamente alle esigenze di applicazioni su larga scala, economiche e precise, fondamentali per la diagnosi precoce del cancro.
NeoGenomics y Ultima Genomics han anunciado una colaboración estratégica para mejorar las capacidades diagnósticas del cáncer utilizando la plataforma de secuenciación UG 100. NeoGenomics ha comprado e instalará el secuenciador UG 100 en su centro de innovación en Cambridge, Reino Unido.
La colaboración aprovecha la tecnología ppmSeq™ de Ultima, que ofrece un secuenciamiento rentable y con bajo margen de error. Las recientes mejoras a través de la cartera Solaris han logrado un aumento de rendimiento de 5 veces, permitiendo una cobertura de 30X con solo 2 nanogramos de ADN, un avance significativo para aplicaciones de biopsia líquida.
Esta asociación tiene como objetivo avanzar en soluciones diagnósticas oncológicas, especialmente en áreas como la detección de enfermedad residual mínima (MRD) y el secuenciamiento del genoma completo. La arquitectura única de la plataforma UG 100 aborda específicamente las necesidades de aplicaciones a gran escala, económicas y precisas para la detección temprana del cáncer.
NeoGenomics와 Ultima Genomics가 UG 100 시퀀싱 플랫폼을 활용하여 암 진단 역량을 강화하기 위한 전략적 협력을 발표했습니다. NeoGenomics는 영국 케임브리지 혁신 센터에 UG 100 시퀀서를 구매하여 설치할 예정입니다.
이번 협력은 비용 효율적이고 오류율이 낮은 시퀀싱을 제공하는 Ultima의 ppmSeq™ 기술을 활용합니다. Solaris 포트폴리오를 통한 최근 개선으로 5배의 수율 향상이 이루어져 단 2나노그램의 DNA로 30X 커버리지를 달성하는 등 액체 생검 응용에 중요한 진전을 이루었습니다.
이 파트너십은 최소 잔여 질환(MRD) 검출 및 전체 유전체 시퀀싱과 같은 분야에서 암 진단 솔루션을 발전시키는 것을 목표로 합니다. UG 100 플랫폼의 독특한 아키텍처는 대규모, 비용 효율적 응용의 요구를 충족시키면서 조기 암 진단을 위한 높은 정확도를 유지합니다.
NeoGenomics et Ultima Genomics ont annoncé une collaboration stratégique visant à améliorer les capacités diagnostiques du cancer grâce à la plateforme de séquençage UG 100. NeoGenomics a acquis et installera le séquenceur UG 100 dans son centre d'innovation de Cambridge, au Royaume-Uni.
Cette collaboration s’appuie sur la technologie ppmSeq™ d’Ultima, qui propose un séquençage à faible coût et à faible taux d’erreur. Les récentes améliorations apportées via le portefeuille Solaris ont permis une augmentation de rendement par 5, permettant une couverture de 30X avec seulement 2 nanogrammes d’ADN – une avancée majeure pour les applications de biopsie liquide.
Ce partenariat vise à faire progresser les solutions diagnostiques en oncologie, notamment dans des domaines tels que la détection de la maladie résiduelle minimale (MRD) et le séquençage du génome complet. L’architecture unique de la plateforme UG 100 répond spécifiquement aux besoins d’applications à grande échelle, économiques et précises, essentielles pour la détection précoce du cancer.
NeoGenomics und Ultima Genomics haben eine strategische Zusammenarbeit angekündigt, um die Krebsdiagnostik mit der UG 100 Sequenzierplattform zu verbessern. NeoGenomics hat den UG 100 Sequencer erworben und wird ihn in ihrem Innovationszentrum in Cambridge, Großbritannien, installieren.
Die Zusammenarbeit nutzt Ultimas ppmSeq™-Technologie, die kostengünstiges und fehlerarmes Sequenzieren ermöglicht. Durch jüngste Verbesserungen im Solaris-Portfolio wurde eine 5-fache Steigerung der Ausbeute erreicht, wodurch eine 30-fache Abdeckung mit nur 2 Nanogramm DNA möglich ist – ein bedeutender Fortschritt für Anwendungen der Flüssigbiopsie.
Diese Partnerschaft zielt darauf ab, onkologische Diagnoselösungen voranzutreiben, insbesondere in Bereichen wie der Erkennung minimaler Resterkrankungen (MRD) und der Ganzgenomsequenzierung. Die einzigartige Architektur der UG 100 Plattform erfüllt speziell die Anforderungen groß angelegter, kosteneffizienter Anwendungen bei gleichzeitig hoher Genauigkeit für die Früherkennung von Krebs.
- Strategic acquisition of UG 100 sequencer enhances NeoGenomics' diagnostic capabilities
- New platform enables cost-effective whole genome sequencing with high accuracy
- Technology allows detection from as little as 2 nanograms of DNA, improving efficiency
- Expansion into fast-growing markets like MRD (Minimal Residual Disease) and liquid biopsy testing
- Partnership with Ultima Genomics strengthens competitive position in precision oncology
- Capital expenditure required for new sequencer purchase
- Implementation and integration costs for new technology platform
Insights
NeoGenomics' acquisition of Ultima's UG 100 sequencer enhances their diagnostic capabilities for advanced cancer detection applications.
The collaboration between NeoGenomics and Ultima Genomics marks a significant technological advancement in precision oncology diagnostics. NeoGenomics' purchase of the UG 100 sequencer positions them to leverage cutting-edge genomic technology with distinct advantages. The platform's cost-effective sequencing profile with extremely low error rates directly addresses key technical challenges in clinical oncology testing.
Ultima's recent Solaris portfolio advancement is particularly noteworthy, as it enables 5x yield improvements and 30X coverage from just 2 nanograms of DNA. These specifications are crucial for applications demanding exceptional sensitivity, such as liquid biopsy where detecting rare cancer signals among normal DNA remains challenging.
The technical specifications make this platform uniquely suited for minimal residual disease (MRD) detection and emerging whole genome sequencing applications in oncology. By installing this system in their Cambridge innovation center, NeoGenomics can accelerate development of tests spanning the entire cancer care continuum.
This technology acquisition directly enhances NeoGenomics' R&D capabilities in developing the high-sensitivity assays increasingly required in modern oncology care, where detecting the proverbial "needle-in-the-haystack" molecular signatures is essential for early detection and treatment monitoring.
NeoGenomics strengthens market position through strategic technology acquisition targeting high-growth oncology diagnostic segments.
This partnership represents a strategic enhancement of NeoGenomics' technological infrastructure and competitive positioning in the oncology diagnostics market. By acquiring Ultima's UG 100 sequencing platform, NeoGenomics is making a calculated investment in capabilities that align with emerging high-value market segments, particularly liquid biopsy and minimal residual disease (MRD) testing.
While financial terms weren't disclosed, the emphasis on the platform's cost-effectiveness suggests potential operational efficiencies for NeoGenomics' test development pipeline. The technology's unique sequencing architecture specifically addresses economic barriers that have historically limited widespread adoption of advanced sequencing applications in clinical settings.
For NeoGenomics, with its established footprint in the oncology ecosystem, this technology acquisition strengthens their position in the precision oncology market. The placement of this technology in their innovation center indicates a focus on test development rather than immediate revenue generation, suggesting this is part of a longer-term growth strategy.
The collaboration targets explicitly mentioned "fast-growing markets in oncology diagnostics" including MRD detection, positioning NeoGenomics to expand their test portfolio in segments where demand is increasing as precision medicine approaches become standard in cancer care.
The UG 100 offers a cost-effective and extremely low-error sequencing profile that is a strong fit for NeoGenomics' emerging clinical assay portfolio that requires large amounts of high-fidelity sequencing data. And with the recent launch of the Solaris portfolio of product advancements, Ultima has now increased sensitivity of variant detection with 5x yield improvements for the SNVQ60 ppmSeq™ mode enabling 30X coverage from as little as 2 nanograms of DNA, making the UG 100 a strong fit for applications like liquid biopsy that require finding a "needle-in-the haystack."
NeoGenomics' R&D team will use Ultima's UG 100 to enable development of tests spanning the cancer care continuum.
"This collaboration with Ultima, a pioneer in cost-efficient whole genome sequencing, will equip our research and development team with resources to rapidly and efficiently translate innovation for the benefit of patient care," said Tony Zook, CEO of NeoGenomics. "With precision oncology testing increasingly being based on next generation sequencing, we are continually looking for targeted opportunities to drive innovation that improve patient outcomes."
"We are excited to be working with NeoGenomics, a leader in cancer diagnostics with a strong and established footprint in the oncology ecosystem. With the UG 100, NeoGenomics is well-positioned to explore fast-growing markets in oncology diagnostics such as MRD and emerging whole genome sequencing applications," said Gilad Almogy, CEO of Ultima Genomics. "Ultima's unique sequencing architecture was designed to specifically meet the needs of cost-effective, large-scale applications and to excel in applications like liquid biopsy requiring extreme accuracy. For oncology applications, our ppmSeq technology offers accuracy at extremely low limits of detection and at low cost, and we believe will be transformational for applications requiring earlier detection such as MRD.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in
About Ultima Genomics
Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com
Contacts
Ultima Media Contact
Vikki Herrera
408-206-7009
vikki@oakstreetcommunications.com
NeoGenomics Investor Contact
Kendra Sweeney
kendra.sweeney@neogenomics.com
NeoGenomics Media Contact
Andrea Sampson
asampson@sampsonprgroup.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/neogenomics-and-ultima-genomics-collaborate-to-expand-clinical-test-offerings-in-oncology-using-the-ug-100-sequencing-platform-302440640.html
SOURCE Ultima Genomics
FAQ
What is the NeoGenomics (NEO) and Ultima Genomics collaboration in 2025?
How will the UG 100 platform benefit NeoGenomics (NEO) oncology testing?
What are the key features of Ultima's ppmSeq technology for NEO's cancer diagnostics?
Where will NeoGenomics (NEO) install the new UG 100 sequencer?
What markets will NeoGenomics (NEO) target with the UG 100 platform?
